UK Device Classification under Annex IX: Classes I to III

1. Key takeaways

The classification of general medical devices in the United Kingdom continues to follow the rule system of Annex IX of Directive 93/42/EEC, as locally modified by Schedule 2A, and divides devices into four classes: I, IIa, IIb and III. Active implantable devices are treated separately under Part III and do not use the four-class scheme at all. Classification is not a labelling exercise: it directly determines the conformity assessment route, whether a United Kingdom approved body must be involved, and the frequency at which the PMSR and PSUR must subsequently be prepared under the post-market surveillance regime. A classification error therefore propagates through the entire compliance file — assessment contracts, certification timelines, surveillance reporting calendars and registration data all inherit the class that was assigned at the start, which is why the classification decision deserves the same rigour as any technical document.

2. Legal basis

The classification provisions draw on both the domestic regulation and the inherited directive texts:

• UK MDR 2002 (SI 2002/618, as amended): regulation 7 (classification of general devices), regulation 4N (the classification criteria in Directives 2003/12 and 2005/50), regulation 4A (transitional provisions for hip, knee and shoulder joint replacements), and Schedule 2A (modifications to the annexes of Directives 90/385, 93/42 and 98/79).
• Directive 93/42/EEC: Annex IX (classification criteria).
• SI 2023/627, regulation 6(4), introduces regulation 19B(3A), adding for Class I devices a determination of whether an approved body’s involvement is required.

Because the domestic provisions invoke the directive annexes rather than restating them, a classification file must cite the rule numbers of Annex IX as applied through Schedule 2A. An analysis that names only the resulting class, without the rules relied upon, is difficult to defend when the registration data or the technical documentation is later examined.

A classification determination also has a cross-checking function within the technical file. Essential requirements conformity, the scope of clinical evaluation and the PMSR/PSUR reporting calendar all reference the class, so a reclassification — however small — touches several documents at once. Companies that treat the class as a single label in the registration data tend to miss these dependencies; the class should therefore appear as a governed field in document control, with a defined impact assessment whenever it changes. Finally, where a device family contains variants, the classification analysis should address each variant expressly rather than assuming that the family conclusion carries over, since a change in invasiveness, duration of use or active function can move a single variant across a class boundary.

3. Expert insights

Insight 1: United Kingdom classification has substantively diverged from the EU MDR. The United Kingdom still applies the 18 rules of Annex IX (the non-invasive, invasive, active and special rules), whereas the EU MDR uses the 22 rules of its Annex VIII. The same product may consequently be assigned to different classes on the two sides — exactly the scenario discussed repeatedly under the international recognition pathway proposals as the case where the United Kingdom class is higher than the European one. Reusing an EU MDR classification conclusion without re-testing it against the Annex IX rules is therefore not a shortcut but a source of error, and the divergence should be documented wherever the outcomes differ.

Insight 2: Class I contains further subdivisions. Class I distinguishes sterile devices (Is), devices with a measuring function (Im) and plain Class I. For the first two, an approved body must be involved in specific conformity assessment modules. The newly inserted regulation 19B(3A), introduced by SI 2023/627, goes further: a device that was Class I under the directives may use the CE transition only if either the conformity assessment under the directives required the involvement of a notified body, or an assessment under the EU MDR would require notified body involvement under Annex IX or Article 52. Devices that satisfy neither condition fall outside the transition and must comply directly.

Insight 3: classification determines the subsequent cost of post-market surveillance. Under Part 4A, Class I devices need only the PMSR (first within 3 years of placing on the market, and thereafter at least every 3 years); Class IIa devices need a PSUR every 2 years; Class IIb and Class III devices need a PSUR every 1 year. Every step up in class materially increases the annual compliance workload, so the classification decision carries a recurring cost consequence, not merely a one-time certification consequence, and it should be budgeted as such at project planning stage.

4. Practical recommendations

GRZAN recommends performing a fresh United Kingdom classification determination for every project, rather than carrying over the EU MDR conclusion as given. The determination memorandum should cite the rule numbers of Annex IX provision by provision, and should expressly record any difference from the European classification together with the reason for it. For devices where the application of a rule is contested, prepare the argumentation material in advance, because the MHRA may request supplementary technical documentation during the registration data verification stage. A well-reasoned, rule-by-rule file converts a potential query into a routine confirmation, and keeps the project timeline protected when scrutiny arrives.

5. Verification checklist

• □ A United Kingdom local classification determination has been completed under Annex IX
• □ Differences from the EU MDR classification and their reasons have been recorded
• □ Class I products have been assessed for the sterile or measuring function subclasses
• □ The PMSR/PSUR preparation frequency has been derived from the class
• □ The classification determination memorandum has been included in the technical documentation

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.